Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based
This activity, Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant Settings, developed in Physicians’ Education Resource®, LLC, (PER®) established Advances in™ legacy format, will highlight best practices in the treatment and management of patients with BRAF-mutated melanoma in the adjuvant setting, including an extensive update on the biologic rationale behind BRAF/MEK inhibitor therapy, the current foundation of evidence in the adjuvant setting for BRAF/MEK inhibitors and checkpoint inhibitors, and the potential of BRAF/MEK targeted therapy in the neoadjuvant setting. Additional focus will be placed on sequencing strategies and adverse events related to BRAF/MEK inhibitor combinations.
You will hear expert perspectives and discussions of recent updates that have changed current treatment paradigms, and the factors that influence melanoma treatment decisions in the adjuvant setting.
By participating in this exciting program, you will learn about:
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists, surgical oncologists, and dermatologists who treat patients with melanoma. Nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals interested in the treatment of melanoma are also invited to participate.
Upon completion of this activity, you should be better prepared to:
Rodabe N. Amaria, MD
Department of Melanoma Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Disclosure: Dr. Amaria has no relevant financial relationships with commercial interests to disclose.
Jonathan S. Zager, MD, FACS
Associate Chief Academic Officer
Chair of Graduate Medical Education
Director of Regional Therapies
Senior Member, Moffitt Cancer Center
Departments of Cutaneous Oncology and Sarcoma
Professor of Surgery, University of South Florida School of Medicine
Moffitt Cancer Center
Disclosure: Grant/Research Support: Delcath Systems, Philogen, Novartis, Castle Biosciences, Provectus; Consultant: Amgen, Delcath Systems; Speaker’s Bureau: Amgen, Array, Sun Pharma
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase Deficiency
Oct 31, 2018
Oct 31, 2018
Oct 31, 2018